Shire Blocks Actavis' Generic Lialda Until 2020

Law360, New York (May 9, 2013, 4:38 PM EDT) -- A Florida federal judge on Thursday blocked Actavis Inc.'s bid to launch a generic version of Shire PLC's inflammatory bowel disease treatment Lialda, ruling that Shire's patent for the drug was both valid and infringed.

Following a five-day bench trial last month, U.S. District Judge Donald M. Middlebrooks said Shire's branded formula of time-released mesalazine was validly patented as U.S. Patent Number 6,773,720, which he said Actavis had infringed when it applied for regulatory approval of a no-name version of Lialda.

The ruling means Actavis will...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.